Zycus Named a LEADER in Supplier Value Management Platforms by Independent Research Firm
17.9.2024 17:00:00 CEST | Business Wire | Press release
Report states: “Zycus excels with its Merlin GenAI capabilities for its SVM suite.”
Zycus, a leading provider of GenAI-powered Source-to-Pay solutions, today announced that it has been recognized as a Leader in The Forrester Wave™: Supplier Value Management (SVM) Platforms, Q3 2024. We believe Zycus’ position as a leader in this prestigious report highlights its commitment to innovation and customer success.
The 9 vendors evaluated were rated on 33 criteria covering current offering, strategy, and market presence with Zycus receiving the top score in the strategy category. Zycus also received the highest possible score in 10 criteria including Vision and Innovation.
The report specifically notes:
- “Zycus uses its exceptional understanding of customer demand to offer a comprehensive SVM suite with a strong go-to-market approach and vision.”
- “Zycus has a compelling vision for the SVM space, and its innovation and strategy tie into this, allowing it to win new clients.”
“Zycus is an ideal partner for organizations seeking an SVM platform that emphasizes product innovation and demonstrates strong customer centricity,” states the report authored by Forrester Senior Analyst, Jeffrey Rajamani.
Forrester’s recognition comes on the heels of Zycus’ success in creating the world’s first GenAI-powered SVM Solution Suite.
"Being named a Leader in the Forrester Wave™ for SVM Platforms is, for us, a testament to our innovation and dedication to meeting customer needs over 2 decades," said Aatish Dedhia, Founder & CEO of Zycus. "Our vision for the future of procurement is to continuously evolve and enhance our solutions through cutting-edge GenAI capabilities."
For more information on Zycus’ Supplier Value Management Suite and its position in the Forrester Wave™, click here.
About Zycus:
Zycus is the leader in Source-to-Pay (S2P) solutions, pioneering the world’s first Generative AI (GenAI) powered platform that helps procurement achieve 10X speed and efficiency. It has been a trusted partner of choice for large global enterprises for over two decades and is consistently recognized by leading industry analysts for its organically built, composable and extensible source-to-pay suite.
Its Merlin GenAI Suite automates tactical tasks, empowering procurement teams to focus on strategic initiatives. Additionally, it offers one-of-its-kind conversational AI, Merlin Assist, for business users, integrated with Microsoft Teams to streamline intake management with a user-friendly experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917321370/en/
Contacts
Arnish Shah
Arnish Shah
Associate Director – Marketing
arnish.shah@zycus.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom